Browse Articles

Discover research articles across all indexed journals

PI3Kα-specific inhibitor BYL-719 synergizes with cisplatin in vitro in PIK3CA-mutated ovarian cancer cells

Scientific Reports Benoît Thibault, Adrien Thole, Romina D’Angelo et al. Feb 20, 2025 DOI: 10.1038/s41598-025-90714-9

Reply to: Human Leukocyte Antigen Mismatching and the Role of Killer Cell Immunoglobulin-Like Receptor Mismatch in Hematopoietic Cell Transplantation for Hematologic Malignancies

Journal of Clinical Oncology Esteban Arrieta-Bolanos, Edouard F. Bonneville, Annalisa Ruggeri et al. Feb 20, 2025 DOI: 10.1200/jco-24-02388

AquaYOLO: Advanced YOLO-based fish detection for optimized aquaculture pond monitoring

Scientific Reports M. Vijayalakshmi, A. Sasithradevi Feb 20, 2025 DOI: 10.1038/s41598-025-89611-y

Abstract Aquaculture plays an important role in ensuring global food security, supporting economic growth, and protecting natural resources. However, traditional methods of monitoring aquatic environments are time-consuming and labor-intensive. To address this, there is growing interest in using computer vision for more efficient aqua monitoring. Fish detection is a key challenging step in these vision-based systems, as it faces challenges such as changing light conditions, varying water clarity, different types of vegetation, and dynamic backgrounds. To overcome these challenges, we introduce a new model called AquaYOLO, an optimized model specifically designed for aquaculture applications. The backbone of AquaYOLO employs CSP layers and enhanced convolutional operations to extract hierarchical features. The head enhances feature representation through upsampling, concatenation, and multi-scale fusion. The detection head uses a precise 40 × 40 scale for box regression and dropping the final C2f layer to ensure accurate localization. To test the AquaYOLO model, we utilize DePondFi dataset (Detection of Pond Fish) collected from aquaponds in South India. DePondFi dataset contains around 50k bounding box annotations across 8150 images. Proposed AquaYOLO model performs well, achieving a precision, recall and mAP@50 of 0.889, 0.848, and 0.909 respectively. Our model ensures efficient and affordable fish detection for small-scale aquaculture.

Hydrogen escaping from a pair of exoplanets smaller than Neptune

Nature R. O. Parke Loyd, Ethan Schreyer, James E. Owen et al. Feb 20, 2025 DOI: 10.1038/s41586-024-08490-x

Comment on the Definition and Interpretation of Complete Mesocolic Excision in the RELARC Trial

Journal of Clinical Oncology Willemijn A. Jongsma, Alexander A.J. Grüter, Boudewijn R. Toorenvliet et al. Feb 20, 2025 DOI: 10.1200/jco-24-02228

Quality of life and clinical data in hemodialysis patients with different degrees of pruritus

Scientific Reports Sebastián Mas Fontao, Paula Manso, Julia Audije-Gil et al. Feb 20, 2025 DOI: 10.1038/s41598-024-83833-2

Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial

Journal of Clinical Oncology Nigel H. Russell, Abin Thomas, Robert K. Hills et al. Feb 20, 2025 DOI: 10.1200/jco.24.00259

PURPOSE To evaluate the survival benefit of chemotherapy intensification in older patients with AML who have not achieved a measurable residual disease (MRD)–negative remission. METHODS Five hundred twenty-three patients with AML (median age, 67 years; range, 51-79) without a flow cytometric MRD-negative remission response after a first course of daunorubicin and AraC (DA; including 165 not in remission) were randomly assigned between up to two further courses of DA or intensified chemotherapy—either fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin (FLAG-Ida) or DA with cladribine (DAC). RESULTS Overall survival (OS) was not improved in the intensification arms (DAC v DA: hazard ratio [HR], 0.74 [95% CI, 0.55 to 1.01]; P = .054; FLAG-Ida v DA: HR, 0.86 [95% CI, 0.66 to 1.12]; P = .270); OS at 3 years was 34%, 46%, and 42% for DA, DAC, and FLAG-Ida, respectively. Early deaths and other adverse events were more frequent with FLAG-Ida (9% day 60 deaths v 4% after DA or DAC; P = .032). Of patients entering random assignment, 131 had MRD unknown status. In this subgroup of patients lacking evidence of residual leukemia by flow cytometry, there was no detectable survival advantage from intensification. A planned sensitivity analysis excluding these patients demonstrated a survival benefit for both DAC (HR, 0.66 [95% CI, 0.46 to 0.93]; P = .018) and FLAG-Ida (HR, 0.72 [95% CI, 0.53 to 0.98]; P = .035); OS at 3 years was 30%, 46%, and 46% for DA, DAC, and FLAG-Ida, respectively. There was a concordant reduction in relapse (DAC v DA: HR, 0.66 [95% CI, 0.45 to 0.98]; P = .039; FLAG-Ida v DA: HR, 0.70 [95% CI, 0.49 to 0.99]; P = .042). DAC benefit was maintained when survival was censored for transplant ( P = .042). CONCLUSION In this study of older patients with AML considered fit and with evidence of residual disease after first induction, chemotherapy intensification improved survival. DAC intensification was better tolerated than FLAG-Ida.

Morning sprint interval training produces greater physical performance adaptations than evening training in soccer players

Scientific Reports Bizheng Yan, Lei Li Feb 20, 2025 DOI: 10.1038/s41598-025-89821-4

Randomized Controlled Trial of Acceptance and Commitment Therapy for Fatigue Interference With Functioning in Metastatic Breast Cancer

Journal of Clinical Oncology Catherine E. Mosher, Shieun Lee, Elizabeth L. Addington et al. Feb 20, 2025 DOI: 10.1200/jco.24.00965

PURPOSE Fatigue is a highly prevalent and disabling symptom for patients with metastatic breast cancer (MBC). Evidence-based interventions for managing fatigue in advanced cancer populations are lacking. This phase II randomized controlled trial tested the effect of acceptance and commitment therapy (ACT) on fatigue interference with functioning in patients with MBC. METHODS Eligible patients were women with stage IV breast cancer who had moderate to severe fatigue interference. Patients completed a baseline assessment that included self-report measures of fatigue interference with activities, mood, and cognition (primary outcome) and sleep interference with functioning, engagement in daily activities, and quality of life (QOL; secondary outcomes). Then patients were randomly assigned to six weekly telephone-delivered sessions of either ACT (n = 116) or education/support (n = 120). Follow-up assessments occurred at 2 weeks, 3 months, and 6 months postintervention (means, 9.69, 20.51, and 33.59 weeks postbaseline, respectively). RESULTS Linear mixed model analyses showed that compared with patients in the education/support condition, patients in the ACT condition reported significantly less fatigue interference ( P = .018). These results were significant at 2 weeks and 6 months postintervention. ACT's effect on sleep interference was not statistically significant after the Sidak adjustment for multiple comparisons ( P = .037). ACT patients showed a steady decline in sleep interference, a trend that was not found for education/support patients. Engagement in daily activities and QOL did not significantly differ between study groups, except for functional QOL ( P = .006). Compared with education/support patients, ACT patients showed significantly better functional QOL at 2 weeks and 6 months postintervention. CONCLUSION Results suggest that a brief, telephone-delivered ACT intervention can reduce fatigue interference with functioning in patients with MBC.

A novel MRI contrast agent NaGdF4@PEG–CLS@MMP-13 NPs for detecting articular cartilage injury

Scientific Reports Jian Xu, Yijun Zhang, Mao Lin et al. Feb 20, 2025 DOI: 10.1038/s41598-025-89444-9

Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations

Journal of Clinical Oncology Jonathan Weitz, Daisuke Nishizaki, Joy Liau et al. Feb 20, 2025 DOI: 10.1200/jco.24.00511

PURPOSE Mucinous neoplasms of the gastrointestinal tract are characterized by a propensity for metastasis to the peritoneum, resulting in peritoneal mucinous carcinomatosis (PMC). A subset of these tumors, most often originating in the appendix, harbor mutations in the GNAS oncogene. While the natural history of GNAS -mutant PMC varies, patient outcomes are generally poor, as is response to cytotoxic chemotherapy. The purpose of this study was to evaluate the clinical efficacy of single-agent palbociclib, a cyclin-dependent kinase (CDK)4/6 inhibitor, in patients with GNAS -mutant PMC. PATIENTS AND METHODS We enrolled 16 patients with PMC in a single-arm personalized cancer therapy trial. For all patients, tumor tissue and/or circulating tumor DNA genomic profiling using next-generation sequencing and, when possible, PD-L1 expression, tumor mutational burden, and microsatellite instability status was assessed. Twelve of 16 patients had previous disease progression on at least one previous line of chemotherapy. The primary tumor was appendix in 13 patients, unknown in two patients, and pancreas in one patient. Eleven cases were classified as low grade, and five as high grade. RESULTS In 13 of 16 patients, we observed a decrease in carcinoembryonic antigen (CEA), and in six patients, the CEA declined by >50%. As measured by clinical and modified peritoneal RECIST criteria, 50% of evaluable patients had stable disease after 12 months of palbociclib. At a median follow-up of 17.6 months, median survival has not been reached. Clinical response to CDK4/6 inhibition was mirrored in tumors with GNAS mutation and mucinous histology using an ex vivo preclinical platform. CONCLUSION CDK4/6 inhibition with palbociclib had clinical activity in PMC characterized by mutations in GNAS that was superior to that previously reported with cytotoxic chemotherapy. CDK4/6 inhibition is a novel therapeutic strategy worthy of further evaluation in this subgroup of gastrointestinal neoplasms.

Study on hydration mechanism and ratio optimization of slag powder modified high-water material

Scientific Reports Xiang Ma, Chenyang Liu, Liwei Zhai et al. Feb 20, 2025 DOI: 10.1038/s41598-025-90028-w

Second MEK Inhibitor Shows Promise in Neurofibromatosis Type 1 With Symptomatic Plexiform Neurofibromas Signaling Hope for Other RASopathies

Journal of Clinical Oncology Simon J. Cook Feb 20, 2025 DOI: 10.1200/jco-24-02375

Author Correction: Sex disparities in outcomes among hospitalizations for heart failure

Scientific Reports Sandeep Appunni, Yanjia Zhang, Atulya A. Khosla et al. Feb 20, 2025 DOI: 10.1038/s41598-025-90402-8

Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline

Journal of Clinical Oncology Evan Y. Yu, R. Bryan Rumble, Neeraj Agarwal et al. Feb 20, 2025 DOI: 10.1200/jco-24-02608

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more . PURPOSE To evaluate evidence on germline and somatic genomic testing for patients with metastatic prostate cancer and provide recommendations. METHODS A systematic review by a multidisciplinary panel with patient representation was conducted. The PubMed database was searched from January 2018 to May 2024. Articles were selected for inclusion if they reported on patients with metastatic prostate cancer who received a germline or somatic genomic test and/or made comparisons between those tests, reported detection rates, prognostic information, or treatment implications. RESULTS A total of 1,713 papers were identified in the literature search. After applying the eligibility criteria, 14 remained: eight systematic reviews and six clinical trials. RECOMMENDATIONS Patients with metastatic prostate cancer should undergo both germline and somatic DNA sequencing using panel-based assays. These tests can guide the use of poly(ADP-ribose) polymerase inhibitors, which have a survival benefit in metastatic castration-resistant prostate cancer. In addition, germline testing may have screening implications for additional cancers for patients and cascade testing implications for family members. The data supporting when to perform repeat testing and optimal tissue type to use (eg, primary tumor v metastatic biopsy versus circulating tumor DNA [ctDNA] testing) are more limited, but this panel recommends considering retesting in patients whose results were previously negative or uninformative, and to consider either a metastatic biopsy or ctDNA when a significant change in clinical status occurs. Next-generation genomic sequencing findings that are associated with prognostic only (and not predictive) value should not be used to guide treatment outside of a clinical trial. Additional information is available at www.asco.org/genitourinary-cancer-guidelines .

Gender-differences in imaging phenotypes of osteoarthritis in the osteoarthritis initiative

Scientific Reports Virginie Kreutzinger, Katharina Ziegeler, Gabby B. Joseph et al. Feb 20, 2025 DOI: 10.1038/s41598-025-90782-x

Abstract In osteoarthritis (OA) research it is increasingly recognized that stratification according to disease phenotypes is essential for optimizing treatment regimens. Gender-specific differences in clinical OA manifestations have been identified, and this analysis aimed to assess whether these differences extend to imaging phenotypes. From the Osteoarthritis Initiative database 2523 participants (1409 women and 1114 men) with completed 3T MRI and whole-organ magnetic resonance imaging scores (WORMS) of the right knee at baseline were included. Imaging phenotypes were assigned based on modified Rapid OsteoArthritis MRI Eligibility Score: the inflammatory, meniscus-cartilage, and bone phenotype. Logistic regression was performed to investigate the effect of gender on phenotype, independent of BMI, race, Kellgren & Lawrence (KL) grade and level of physical activity. Female gender was independently associated with lower odds for the meniscus-cartilage (OR 0.61, 95%CI 0.47–0.80, p < 0.001) but not for the inflammatory (OR 1.04, 95%CI 0.89–1.24, p = 0.697) or the subchondral bone phenotype (OR 1.13, 95%CI 0.95–1.36, p = 0.166). This difference highlights an opportunity for future refinements to better accommodate gender/sex differences in disease trajectories while investigating different treatment regimes in knee OA.

Second Primary Cancer Risks After Breast Cancer in <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers

Journal of Clinical Oncology Isaac Allen, Hend Hassan, Yvonne Walburga et al. Feb 20, 2025 DOI: 10.1200/jco.24.01146

PURPOSE Second primary cancer (SPC) risks after breast cancer (BC) in BRCA1/BRCA2 pathogenic variant (PV) carriers are uncertain. We estimated relative and absolute risks using a novel linkage of genetic testing data to population-scale National Disease Registration Service and Hospital Episode Statistics electronic health records. METHODS We followed 25,811 females and 480 males diagnosed with BC and tested for germline BRCA1/BRCA2 PVs in NHS Clinical Genetics centers in England between 1995 and 2019 until SPC diagnosis, death, migration, contralateral breast/ovarian surgery plus 1 year, or the 31st of December 2020. We estimated standardized incidence ratios (SIRs) using English population incidences, hazard ratios (HRs) comparing carriers to noncarriers using Cox regression, and Kaplan-Meier 10-year cumulative risks. RESULTS There were 1,840 BRCA1 and 1,750 BRCA2 female PV carriers. Compared with population incidences, BRCA1 carriers had elevated contralateral BC (CBC; SIR, 15.6 [95% CI, 11.8 to 20.2]), ovarian (SIR, 44.0 [95% CI, 31.4 to 59.9]), combined nonbreast/ovarian (SIR, 2.18 [95% CI, 1.59 to 2.92]), colorectal (SIR, 4.80 [95% CI, 2.62 to 8.05]), and endometrial (SIR, 2.92 [95% CI, 1.07 to 6.35]) SPC risks. BRCA2 carriers had elevated CBC (SIR, 7.70 [95% CI, 5.45 to 10.6]), ovarian (SIR, 16.8 [95% CI, 10.3 to 26.0]), pancreatic (SIR, 5.42 [95% CI, 2.09 to 12.5]), and combined nonbreast/ovarian (SIR, 1.68 [95% CI, 1.24 to 2.23]) SPC risks. Compared with females without BRCA1/BRCA2 PVs on testing, BRCA1 carriers had elevated CBC (HR, 3.60 [95% CI, 2.65 to 4.90]), ovarian (HR, 33.0 [95% CI, 19.1 to 57.1]), combined nonbreast/ovarian (HR, 1.45 [95% CI, 1.05 to 2.01]), and colorectal (HR, 2.93 [95% CI, 1.53 to 5.62]) SPC risks. BRCA2 carriers had elevated CBC (HR, 2.40 [95% CI, 1.70 to 3.40]), ovarian (HR, 12.0 [95% CI, 6.70 to 21.5]), and pancreatic (HR, 3.56 [95% CI, 1.34 to 9.48]) SPC risks. Ten-year cumulative CBC, ovarian, and combined nonbreast/ovarian cancer risks were 16%/6.3%/7.8% ( BRCA1 carriers), 12%/3.0%/6.2% ( BRCA2 carriers), and 3.6%/0.4%/4.9% (noncarriers). Male BRCA2 carriers had higher CBC (HR, 13.1 [95% CI, 1.19 to 146]) and prostate (HR, 5.61 [95% CI, 1.96 to 16.0]) SPC risks than noncarriers. CONCLUSION Survivors of BC carrying BRCA1 and BRCA2 PVs are at high SPC risk. They may benefit from enhanced surveillance and risk-reduction measures.

Factors affecting visual outcome in patients with toxic optic neuropathy caused by ethambutol

Scientific Reports Kwang Eon Han, Heejin Yoon, Heeyoung Choi et al. Feb 20, 2025 DOI: 10.1038/s41598-025-90663-3

Gourmet cockatoos like to fancy up their food

Nature Feb 20, 2025 DOI: 10.1038/d41586-025-00400-z

Reply to: Significance of Up-Front Stereotactic Radiosurgery for Non–Small Cell Lung Cancer Patients With Brain Metastases in the Era of New Generation Tyrosine Kinase Inhibitors

Journal of Clinical Oncology Chad G. Rusthoven, Emily Miao, Lillian A. Boe et al. Feb 20, 2025 DOI: 10.1200/jco-24-02129